Acanthosis nigricans in a patient treated with palifermin.
Palifermin is a modified human keratinocyte growth factor (KGF) given to decrease the incidence and duration of severe oral mucositis in patients receiving myelotoxic chemotherapy followed by a hematopoietic stem cell transplant. We report a case of a 42-year-old man who developed acanthosis nigricans after taking palifermin.
Department of Dermatology, The State University of New York, Buffalo, USA.
Melvin
M
Lee
Marcelle
M
Grassi
D000052:Acanthosis Nigricans / Q000139:chemically induced*; D000328:Adult; D018240:Endodermal Sinus Tumor / Q000628:therapy; D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000628:therapy; D013280:Stomatitis / Q000209:etiology / Q000517:prevention & control*
D051523:Fibroblast Growth Factor 7